← Back
Data updated: Jul 17, 2026
MSP Vaccine Company
Biotech Pharmaceuticals
MSP Vaccine Company is a biotechnology company with 1 FDA-approved products.
2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics
MSP Vaccine Company's Key Drugs
MSP Vaccine Company's core commercial portfolio centers on Vaxelis — its most strategically important drugs approved in the last 15 years.
MSP Vaccine Company's Recent FDA Approvals
New NDA/BLA approvals for MSP Vaccine Company over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
MSP Vaccine Company's Therapeutic Areas
Disease areas where MSP Vaccine Company has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
MSP Vaccine Company Pipeline Snapshot
Active clinical trials for MSP Vaccine Company across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Vaxelis leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2018-12-20
- Latest
- 2018-12-20
- Applications
- 1